tiprankstipranks
Immunovant, Inc. (IMVT)
NASDAQ:IMVT
US Market
IMVT
Immunovant
RESEARCH TOOLSreports
Want to see IMVT full AI Analyst Report?

Immunovant (IMVT) Stock Forecast & Price Target

929 Followers
See the Price Targets and Ratings of:

IMVT Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Immunovant
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMVT Stock 12 Month Forecast

Average Price Target

$41.57
▲(41.88% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $41.57 with a high forecast of $66.00 and a low forecast of $23.00. The average price target represents a 41.88% change from the last price of $29.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","67":"$67","27.25":"$27.3","40.5":"$40.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.57142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,27.25,40.5,53.75,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.1,28.24615384615385,31.392307692307693,34.53846153846154,37.684615384615384,40.830769230769235,43.97692307692308,47.12307692307692,50.269230769230774,53.41538461538462,56.56153846153846,59.707692307692305,62.853846153846156,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.1,26.36703296703297,27.634065934065934,28.9010989010989,30.16813186813187,31.435164835164834,32.7021978021978,33.96923076923077,35.23626373626374,36.5032967032967,37.77032967032967,39.037362637362634,40.3043956043956,{"y":41.57142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.1,24.93846153846154,24.77692307692308,24.615384615384617,24.453846153846154,24.292307692307695,24.130769230769232,23.96923076923077,23.807692307692307,23.646153846153847,23.484615384615385,23.323076923076922,23.161538461538463,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$66.00Average Price Target$41.57Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IMVT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$66
Buy
125.26%
Upside
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Immunovant (NASDAQ: IMVT) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on IMVT
Corinne Johnson
Goldman Sachs
Goldman Sachs
$29→$32
Hold
9.22%
Upside
Assigned
04/15/26
Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs
LifeSci Capital Analyst forecast on IMVT
Sam Slutsky
LifeSci Capital
LifeSci Capital
$50→$42
Buy
43.34%
Upside
Reiterated
04/11/26
Lowering our price target to $42/share from $50/share
Wolfe Research Analyst forecast on IMVT
Andy Chen
Wolfe Research
Wolfe Research
$47
Buy
60.41%
Upside
Reiterated
04/06/26
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
Stifel Nicolaus Analyst forecast on IMVT
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$25.1→$49
Buy
67.24%
Upside
Assigned
04/04/26
Analysts Offer Insights on Healthcare Companies: Tilray (NASDAQ: TLRY), Immunovant (NASDAQ: IMVT) and Palvella Therapeutics (NASDAQ: PVLA)
Leerink Partners Analyst forecast on IMVT
Thomas Smith
Leerink Partners
Leerink Partners
$52→$50
Buy
70.65%
Upside
Reiterated
04/02/26
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
Wells Fargo Analyst forecast on IMVT
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$65→$45
Buy
53.58%
Upside
Reiterated
04/01/26
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)
Bernstein Analyst forecast on IMVT
William Pickering
Bernstein
Bernstein
$28
Hold
-4.44%
Downside
Initiated
03/20/26
Immunovant initiated with a Market Perform at BernsteinImmunovant initiated with a Market Perform at Bernstein
H.C. Wainwright Analyst forecast on IMVT
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$35
Buy
19.45%
Upside
Reiterated
02/17/26
Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)
Guggenheim Analyst forecast on IMVT
Yatin Suneja
Guggenheim
Guggenheim
$41→$44
Buy
50.17%
Upside
Reiterated
02/09/26
Immunovant price target raised to $44 from $41 at GuggenheimImmunovant price target raised to $44 from $41 at Guggenheim
Truist Financial Analyst forecast on IMVT
Danielle Brill
Truist Financial
Truist Financial
$22→$23
Hold
-21.50%
Downside
Reiterated
02/09/26
Immunovant price target raised to $23 from $22 at TruistImmunovant price target raised to $23 from $22 at Truist
Oppenheimer Analyst forecast on IMVT
Leland Gershell
Oppenheimer
Oppenheimer
$54
Buy
84.30%
Upside
Reiterated
02/09/26
Immunovant (IMVT) Gets a Buy from Oppenheimer
J.P. Morgan Analyst forecast on IMVT
Brian Cheng
J.P. Morgan
J.P. Morgan
$34→$35
Buy
19.45%
Upside
Reiterated
02/09/26
Immunovant (IMVT) Receives a Buy from J.P. Morgan
Bank of America Securities Analyst forecast on IMVT
Dina Ramadane
Bank of America Securities
Bank of America Securities
$32
Buy
9.22%
Upside
Reiterated
02/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on IMVT
Samantha Semenkow
Citi
Citi
$58→$57
Buy
94.54%
Upside
Reiterated
08/12/25
Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IMVT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$66
Buy
125.26%
Upside
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Immunovant (NASDAQ: IMVT) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on IMVT
Corinne Johnson
Goldman Sachs
Goldman Sachs
$29→$32
Hold
9.22%
Upside
Assigned
04/15/26
Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs
LifeSci Capital Analyst forecast on IMVT
Sam Slutsky
LifeSci Capital
LifeSci Capital
$50→$42
Buy
43.34%
Upside
Reiterated
04/11/26
Lowering our price target to $42/share from $50/share
Wolfe Research Analyst forecast on IMVT
Andy Chen
Wolfe Research
Wolfe Research
$47
Buy
60.41%
Upside
Reiterated
04/06/26
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
Stifel Nicolaus Analyst forecast on IMVT
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$25.1→$49
Buy
67.24%
Upside
Assigned
04/04/26
Analysts Offer Insights on Healthcare Companies: Tilray (NASDAQ: TLRY), Immunovant (NASDAQ: IMVT) and Palvella Therapeutics (NASDAQ: PVLA)
Leerink Partners Analyst forecast on IMVT
Thomas Smith
Leerink Partners
Leerink Partners
$52→$50
Buy
70.65%
Upside
Reiterated
04/02/26
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
Wells Fargo Analyst forecast on IMVT
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$65→$45
Buy
53.58%
Upside
Reiterated
04/01/26
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)
Bernstein Analyst forecast on IMVT
William Pickering
Bernstein
Bernstein
$28
Hold
-4.44%
Downside
Initiated
03/20/26
Immunovant initiated with a Market Perform at BernsteinImmunovant initiated with a Market Perform at Bernstein
H.C. Wainwright Analyst forecast on IMVT
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$35
Buy
19.45%
Upside
Reiterated
02/17/26
Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)
Guggenheim Analyst forecast on IMVT
Yatin Suneja
Guggenheim
Guggenheim
$41→$44
Buy
50.17%
Upside
Reiterated
02/09/26
Immunovant price target raised to $44 from $41 at GuggenheimImmunovant price target raised to $44 from $41 at Guggenheim
Truist Financial Analyst forecast on IMVT
Danielle Brill
Truist Financial
Truist Financial
$22→$23
Hold
-21.50%
Downside
Reiterated
02/09/26
Immunovant price target raised to $23 from $22 at TruistImmunovant price target raised to $23 from $22 at Truist
Oppenheimer Analyst forecast on IMVT
Leland Gershell
Oppenheimer
Oppenheimer
$54
Buy
84.30%
Upside
Reiterated
02/09/26
Immunovant (IMVT) Gets a Buy from Oppenheimer
J.P. Morgan Analyst forecast on IMVT
Brian Cheng
J.P. Morgan
J.P. Morgan
$34→$35
Buy
19.45%
Upside
Reiterated
02/09/26
Immunovant (IMVT) Receives a Buy from J.P. Morgan
Bank of America Securities Analyst forecast on IMVT
Dina Ramadane
Bank of America Securities
Bank of America Securities
$32
Buy
9.22%
Upside
Reiterated
02/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on IMVT
Samantha Semenkow
Citi
Citi
$58→$57
Buy
94.54%
Upside
Reiterated
08/12/25
Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

3 Months
xxx
Success Rate
12/20 ratings generated profit
60%
Average Return
+22.02%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +22.02% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
12/20 ratings generated profit
60%
Average Return
+59.15%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +59.15% per trade.
2 Years
xxx
Success Rate
13/20 ratings generated profit
65%
Average Return
+72.86%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 65.00% of your transactions generating a profit, with an average return of +72.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
5
5
6
4
11
Buy
4
5
5
5
4
Hold
3
3
4
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
13
15
12
18
In the current month, IMVT has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is 41.57.
Each month's total comprises the sum of three months' worth of ratings.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.60 with a range of -$0.71 to -$0.52. The previous quarter’s EPS was -$0.61. IMVT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMVT is -$0.60 with a range of -$0.71 to -$0.52. The previous quarter’s EPS was -$0.61. IMVT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.
No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.
Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunovant, Inc.’s 12-month average price target is 41.57.
    What is IMVT’s upside potential, based on the analysts’ average price target?
    Immunovant, Inc. has 41.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMVT a Buy, Sell or Hold?
          Immunovant, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Immunovant, Inc.’s price target?
            The average price target for Immunovant, Inc. is 41.57. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $66.00 ,the lowest forecast is $23.00. The average price target represents 41.88% Increase from the current price of $29.3.
              What do analysts say about Immunovant, Inc.?
              Immunovant, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of IMVT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.